Mengelers M J, Van Gogh E R, Kuiper H A, Pijpers A, Verheijden J H, Van Miert A S
State Institute for Quality Control of Agricultural Products, Department of Toxicology, Wageningen, The Netherlands.
J Vet Pharmacol Ther. 1995 Aug;18(4):243-53. doi: 10.1111/j.1365-2885.1995.tb00588.x.
The pharmacokinetics of two sulfonamide/trimethoprim combinations were investigated after intravenous administration to clinically healthy pigs and to the same pigs following a challenge with Actinobacillus pleuropneumoniae toxins. Endobronchial challenge with A. pleuropneumoniae toxins resulted in fever, increased white blood cell counts and decreased water and feed consumption. Healthy, as well as febrile, pigs were given sulfadimethoxine (SDM) or sulfamethoxazole (SMX) intravenously at a dose of 25 mg/kg b.w. in combination with 5 mg trimethoprim (TMP) per kg body weight. The pharmacokinetic parameters of the sulfonamides as well as their main metabolites (acetyl sulfonamides) were not significantly different in healthy and febrile pigs. In healthy and pneumonic pigs, the mean elimination half-lives of SDM were 12.9 h and 13.4 h, respectively, those of SMX 2.5 h and 2.7 h, respectively, and those of TMP 2.8 h and 2.6 h, respectively. Distribution volumes in healthy and febrile pigs of SDM and SMX varied between 0.2 and 0.4 L/kg, and those of TMP between 1.1 and 1.6 L/kg. The mean AUC of TMP was decreased and the volume of distribution and total body clearance of TMP were increased in febrile pigs. Protein binding of the drugs and metabolites studied were not significantly changed after toxin-induced fever. The extent of protein binding of SDM, SMX and TMP was in the range 94-99%, 45-56% and 40-50%, respectively. Based on knowledge of in vitro antimicrobial activity of the drug combinations against A. pleuropneumoniae it was concluded that after intravenous administration of the dose administered (30 mg/kg of the combination preparations) to healthy and pneumonic pigs, plasma concentrations of SMX and TMP were above the concentration required for growth inhibition of 50% of A., pleuropneumoniae strains for approximately 16 h, whereas bacteriostatic plasma concentrations of SDM were still present after TMP had been eliminated from plasma. Because of similar elimination half-lives of SMX and TMP in pigs this combination is preferred to the combination of SDM with TMP.
在对临床健康猪静脉注射两种磺胺类/甲氧苄啶组合药物后,以及在用胸膜肺炎放线杆菌毒素攻击同一批猪之后,研究了这两种组合药物的药代动力学。用胸膜肺炎放线杆菌毒素进行支气管内攻击导致发热、白细胞计数增加以及水和饲料摄入量减少。健康猪和发热猪均以25mg/kg体重的剂量静脉注射磺胺二甲氧嘧啶(SDM)或磺胺甲恶唑(SMX),并与每千克体重5mg甲氧苄啶(TMP)联合使用。在健康猪和发热猪中,磺胺类药物及其主要代谢产物(乙酰磺胺类)的药代动力学参数没有显著差异。在健康猪和患肺炎的猪中,SDM的平均消除半衰期分别为12.9小时和13.4小时,SMX的分别为2.5小时和2.7小时,TMP的分别为2.8小时和2.6小时。健康猪和发热猪中SDM和SMX的分布容积在0.2至0.4L/kg之间,TMP的分布容积在1.1至1.6L/kg之间。发热猪中TMP的平均曲线下面积(AUC)降低,TMP的分布容积和全身清除率增加。毒素诱导发热后,所研究药物及其代谢产物的蛋白结合没有显著变化。SDM、SMX和TMP的蛋白结合程度分别在94 - 99%、45 - 56%和40 - 50%的范围内。基于对药物组合对胸膜肺炎放线杆菌的体外抗菌活性的了解,得出结论:在对健康猪和患肺炎的猪静脉注射给药剂量(30mg/kg组合制剂)后,SMX和TMP的血浆浓度在大约16小时内高于抑制50%胸膜肺炎放线杆菌菌株生长所需的浓度,而在TMP从血浆中消除后,SDM的抑菌血浆浓度仍然存在。由于猪体内SMX和TMP的消除半衰期相似,因此该组合比SDM与TMP的组合更受青睐。